ACS Register

ACS Industry Symposium Global Challenges and Recent Advances in Biologics and Biosimilars Mumbai, India 14-15 Dec 2017

Share this event:
Join the Symposium! REGISTER
0 Days
0 Hours
0 Minutes
0 Seconds
Join the Symposium! REGISTER
0 Days
0 Hours
0 Minutes
0 Seconds

Programming

The ACS Industry Symposium: Global Challenges and Recent Advances in Biologics and Biosimilars will focus on connecting top researchers and industry experts in biologics and biosimilars on topics such as immunotherapy, protein design, protein chemistry, and biopharmaceutical development, among others. The program includes keynote presentations, panel discussions, and ample networking opportunities.

For additional reading about biologics and biosimilars, please download this white paper.
Biopharmaceutical Chemistry Research & Development White Paper

Agenda

14 DEC
15 DEC
Thursday, 14 DEC 1
Friday, 15 Dec 2
clock7:45 REGISTRATION
clock8:30 Opening Ceremony and Meeting Overview Krishna Kumar, Professor, Chairman of the Chemistry Department, Tufts University, USA Peter Senter, VP, Chemistry, Seattle Genetics, USA Vijay Kuruganti, Director, ACS Industry Member Programs, USA
Session 1: Vaccines
clock9:00 Enabling Innovation and Partnerships in Life Sciences to Improve Health for All Harish Iyer, Senior Advisor, Scientific Programs, Bill and Melinda Gates Foundation, India
clock9:50 Glycocconjugate Vaccines against Bacterial Infections Based on Synthetic Glycans Peter Seeberger, Director, Max Planck Institute of Colloids and Interfaces, Germany
clock10:40 TEA BREAK AND NETWORKING
Session 2: New Developments in Protein Biologics
clock10:55 Design and Evolution of Artificial Enzymes Donald Hilvert, Professor, Laboratory of Organic Chemistry, ETH Zürich, Switzerland

clock11:45 Design of Peptide Therapeutics against Global Diseases Krishna Kumar, Professor, Chairman of the Chemistry Department, Tufts University, USA
clock12:35 – 14:00 LUNCH
Session 3: Development of Novel Drugs
clock14:00 Developing and Launching Exemptia™ as the First Biosimilar of Adalimumab Sanjeev Kumar, Senior Vice President, Biologics and Biosimilar Division, Zydus Cadila, India
clock14:45 Antibody-Drug Conjugates: Challenges in Translating Preclinical Success into Clinical Reality in Cancer Therapy Nitin Damle, Senior Vice President and Head, Discovery Biology, Preclinical R&D/CSO Sun Pharma Advanced Research Company, Ltd. (SPARC) , India
clock15:35 TEA BREAK AND NETWORKING
clock16:05 Antibody-Based Therapeutics for Cancer Therapy Peter Senter, VP, Chemistry, Seattle Genetics, USA
clock16:55 Highlights from Day 1 Krishna Kumar, Professor, Chairman of the Chemistry Department, Tufts University, USA
clock17:30 - 20:00 RECEPTION